Startups
Edit
Light Chain Bioscience | Novimmune SA
http://www.lightchainbio.com/Last activity: 16.08.2022
Active
NovImmune has successfully divested EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019.
NovImmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand as:
“Light Chain Bioscience – A brand of Novimmune SA”.
The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function.
A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop.
Thus far, NovImmune has advanced seven drug candidates to treat a range of conditions. The Company’s pipeline is a balance of preclinical and clinical candidates for validated and novel targets. NovImmune has established a next-generation antibody drug discovery platform that includes novel bispecific antibody drug capabilities - the simple, stable and smart kappa-lambda-body™.
In 2009, NovImmune received the European Biotechnica Award. In 2010, NovImmune entered a partnership with Genentech to advance the Company’s anti-IL17 drug candidate. In addition to pursuing additional drug discovery, development and commercialization partnerships, the Company plans to bring selected drugs to market for focused applications.
NovImmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand as:
“Light Chain Bioscience – A brand of Novimmune SA”.
The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function.
A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop.
Thus far, NovImmune has advanced seven drug candidates to treat a range of conditions. The Company’s pipeline is a balance of preclinical and clinical candidates for validated and novel targets. NovImmune has established a next-generation antibody drug discovery platform that includes novel bispecific antibody drug capabilities - the simple, stable and smart kappa-lambda-body™.
In 2009, NovImmune received the European Biotechnica Award. In 2010, NovImmune entered a partnership with Genentech to advance the Company’s anti-IL17 drug candidate. In addition to pursuing additional drug discovery, development and commercialization partnerships, the Company plans to bring selected drugs to market for focused applications.
Overview
Location
Switzerland, Geneva, Plan-les-Ouates
Employees
51-200
Total raised
$29.8M
Founded date
1998
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 16, 2022 | Light Chain Bioscience doses first patients with solid cancers | |
| Apr 19, 2022 | Light Chain Bioscience Adopts Genedata Biologics for Next-Gen Antibody Engineering | "Genedata Biologics will act as our organizational memory to structure and protect our assets and ensure that data can always be accessed and found,” said Nicolas Fischer, Ph.D., CEO at Light Chain Bioscience. BASEL, Switzerland (PRWEB... |
Reviews 0
FAQ about Light Chain Bioscience | Novimmune SA
When was Light Chain Bioscience | Novimmune SA founded?
Light Chain Bioscience | Novimmune SA was founded in 1998.
How much funding has Light Chain Bioscience | Novimmune SA raised?
Light Chain Bioscience | Novimmune SA has raised $29.8M in total across 1 funding round.
What has the press written about Light Chain Bioscience | Novimmune SA?
Parsers VC has collected 3 articles mentioning Light Chain Bioscience | Novimmune SA, among them “Light Chain Bioscience doses first patients with solid cancers” (Aug 16, 2022) and “Light Chain Bioscience Adopts Genedata Biologics for Next-Gen Antibody Engineering” (Apr 19, 2022).
Is Light Chain Bioscience | Novimmune SA still active?
Yes, Light Chain Bioscience | Novimmune SA is active; its latest activity on Parsers VC dates from Aug 16, 2022.